Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study Examining the Feasibility of Intermittent Convection-Enhanced Delivery (CED) of MTX110 for the Treatment of Children With Newly Diagnosed Diffuse Midline Gliomas

NCT04264143 is registered in ClinicalTrials.gov with Luca Szalontay as lead sponsor.

NCT NCT04264143
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04264143 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study Examining the Feasibility of Intermittent Convection-Enhanced Delivery (CED) of MTX110 for the Treatment of Children With Newly Diagnosed Diffuse Midline Gliomas
Lead sponsor
Luca Szalontay
Phase
Phase 1
Overall status
Completed
Start date
March 10, 2020
Completion date
November 22, 2023
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse intrinsic pontine glioma, diffuse midline glioma, diffuse pontine and thalamic gliomas